TM-25659-Induced Activation of FGF21 Level Decreases Insulin Resistance and Inflammation in Skeletal Muscle via GCN2 Pathways |
Jung, Jong Gab
(Department of Endocrinology and Metabolism, Ajou University School of Medicine)
Yi, Sang-A (Department of Endocrinology and Metabolism, Ajou University School of Medicine) Choi, Sung-E (Department of Physiology, Ajou University School of Medicine) Kang, Yup (Department of Physiology, Ajou University School of Medicine) Kim, Tae Ho (Division of Endocrine and Metabolism, Department of Internal Medicine, Seoul Medical Center) Jeon, Ja Young (Department of Endocrinology and Metabolism, Ajou University School of Medicine) Bae, Myung Ae (Korea Research Institute of Chemical Technology, University of Science & Technology) Ahn, Jin Hee (Korea Research Institute of Chemical Technology, University of Science & Technology) Jeong, Hana (College of Pharmacy, Graduate School of Pharmaceutical Sciences, and Global Top5 Research Program, Ewha Womans University) Hwang, Eun Sook (College of Pharmacy, Graduate School of Pharmaceutical Sciences, and Global Top5 Research Program, Ewha Womans University) Lee, Kwan-Woo (Department of Endocrinology and Metabolism, Ajou University School of Medicine) |
1 | Anthony, T.G., McDaniel, B.J., Byerley, R.L., McGrath, B.C., Cavener, D.R., McNurlan, M.A., and Wek, R.C. (2004). Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2kinase GCN2. J. Biol. Chem. 279, 36553-36561. DOI |
2 | Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., and Maratos-Flier, E. (2007) Hepatic fibroblast growth factor 21 is regulated by PPAR alpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5, 426-437. DOI |
3 | De Sousa-Coelho, A.L., Relat, J., Hondares, E., Perez-Marti, A., Ribas, F., Villarroya, F., Marrero, P.F., and Haro, D. (2013). FGF21 mediates the lipid metabolism response to amino acid starvation. J. Lipid Res. 54, 1786-1797. DOI |
4 | Fisher, F.M., Chui, P.C., Antonellis, P.J., Bina, H.A., Kharitonenkov, A., Flier, J.S., and Maratos-Flier, E. (2010). Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781-2789. DOI |
5 | Ge, X., Wang, Y., Lam, K.S., and Xu, A. (2012). Metabolic actions of FGF21: molecular mechanisms and therapeutic implications. Acta Pharmaceutica Sinica B. 2, 350-357. DOI |
6 | Guo, F., and Cavener, D.R. (2007). The GCN2 eIF2alpha kinase regulates fatty-acid homeostasis in the liver during deprivation of an essential amino acid. Cell Metabol. 5, 1-12. DOI |
7 | Hong, J.H., Hwang, E.S., McManus, M.T., Amsterdam, A., Tian, Y., Kalmukova, R., Mueller, E., Benjamin, T., Spiegelman, B.M., Sharp, P.A., et al. (2005) TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309, 1074-1078. DOI |
8 | Huh J.Y., Park Y.J., Ham M., and Kim J.B. (2014) Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol. Cells 37, 365-371. DOI |
9 | Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007). Endocrine regulation of the fasting response by PPAR alpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415-425. DOI |
10 | Jang, E.J., Jeong, H., Kang, J.O., Kim, N.J., Kim, M.S., Choi, S.H., Yoo, S.E., Hong, J.H., Bae, M.A., and Hwang, E.S. (2012). TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional coactivator TAZ. Br. J. Pharmacol. 165, 1584-1594. DOI |
11 | Jung, J.G., Choi, S.E., Hwang, Y.J., Lee, S.A., Kim, E.K., Lee, M.S., Han, S.J., Kim, H.J., Kim, D.J., Kang, Y., et al. (2011). Supplementation of pyruvate prevents palmitate-induced impairment of glucose uptake in C2 myotubes. Mol. Cell Endocrinol. 345, 79-87. DOI |
12 | Laeger, T., Henagan, T.M., Albarado, D.C., Redman, L.M., Bray, G.A., Noland, R.C., Munzberg, H., Hutson, S.M., Gettys, T.W., Schwartz, M.W., et al. (2014). FGF21 is an endocrine signal of protein restriction. J. Clin. Invest. 124, 3913-3922. DOI |
13 | Kanai, F., Marignani, P.A., Sarbassova, D., Yagi, R., Hall, R.A., Donowitz, M., Hisaminato, A., Fujiwara, T., Ito, Y., Cantley, L.C., et al. (2000). TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19, 6778-6791. DOI |
14 | Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., et al. (2005). FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635. DOI |
15 | Kim, K.H., Jeong, Y.T., Oh, H., Kim, S.H., Cho, J.M., Kim, Y.N., Kim, S.S., Kim, D.H., Hur, K.Y., Kim, H.K., et al. (2013). Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 19, 83-92. DOI |
16 | Lees, E.K., Krol, E., Grant, L., Shearer, K., Wyse, C., Moncur, E., Bykowska, A.S., Mody, N., Gettys, T.W., and Delibegovic, M. (2014). Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21. Aging Cell. 13, 817-827. DOI |
17 | Lin, Z., Tian, H., Lam, K.S., Lin, S., Hoo, R.C., Konishi, M., Itoh, N., Wang, Y., Bornstein, S.R., Xu, A., et al. (2013). Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17, 779-789. DOI |
18 | Ota, T. (2013). Chemokine systems link obesity to insulin resistance. Diabetes Metab. J. 37, 165-172. DOI |
19 | Wang, W.F., Li, S.M., Ren, G.P., Zheng, W., Lu, Y.J., Yu, Y.H., Xu, W.J., Li, T.H., Zhou, L.H., Liu, Y., et al. (2015) Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats. Endocrine 49, 119-129. DOI |
20 | Park, S., Sadanala K.C., and Kim E.K. (2015). A metabolomic approach to understanding the metabolic link between obesity and diabetes. Mol. Cells 38, 587-596 DOI |
21 | Wilson, G.J., Bunpo, P., Cundiff, J.K., Wek, R.C., and Anthony, T.G. (2013). The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment. Am J. Physiol. Endocrinol. Metab. 305, 1124-1133. DOI |
22 | Woo, Y.C., Xu, A., Wang, Y., and Lam, K.S. (2013). Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol. 78, 489-496. DOI |
23 | Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S, Tartaglia, L.A., et al. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830. DOI |
24 | Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.S., Lindberg, R.A., et al. (2009). Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in dietinduced obese mice. Diabetes 58, 250-259. DOI |
![]() |